ProfileGDS5678 / 1429376_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 90% 93% 92% 91% 91% 92% 89% 89% 91% 91% 91% 92% 89% 91% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.1511390
GSM967853U87-EV human glioblastoma xenograft - Control 27.8706693
GSM967854U87-EV human glioblastoma xenograft - Control 37.6992192
GSM967855U87-EV human glioblastoma xenograft - Control 47.5327291
GSM967856U87-EV human glioblastoma xenograft - Control 57.4245891
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.4845392
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.7687589
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.8999889
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.2694191
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.4716691
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.3556191
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.6384892
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.9599889
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.4764691